Abstract
A 50% rate of early virological failure associated with the selection of resistance mutations was seen in a group of 14 antiretroviral-naive adults who initiated highly active antiretroviral therapy with tenofovir and didanosine plus efavirenz or nevirapine. At month 6, the mutations detected were K65R, L74V, L100I, K103N/R/T, Y181C and G190E/Q/S. These results argue against the use of tenofovir plus didanosine in HIV-infected antiretroviral-naive adults even when the third drug is a non-nucleoside reverse transcriptase inhibitor.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives*
-
Adult
-
Aged
-
Alkynes
-
Antiretroviral Therapy, Highly Active / methods*
-
Benzoxazines
-
Cyclopropanes
-
Didanosine / administration & dosage*
-
Drug Resistance, Viral
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy*
-
HIV-1 / genetics*
-
Humans
-
Male
-
Middle Aged
-
Nevirapine / adverse effects*
-
Organophosphonates / administration & dosage*
-
Oxazines / administration & dosage*
-
RNA, Viral / analysis
-
Reverse Transcriptase Inhibitors / administration & dosage
-
Tenofovir
Substances
-
Alkynes
-
Benzoxazines
-
Cyclopropanes
-
Organophosphonates
-
Oxazines
-
RNA, Viral
-
Reverse Transcriptase Inhibitors
-
Nevirapine
-
Tenofovir
-
Adenine
-
efavirenz
-
Didanosine